Reducing the Burden of Cytomegalovirus in HCT: Optimal Strategy for Prevention

Reducing the Burden of Cytomegalovirus in HCT: Optimal Strategy for Prevention

ReachMD Healthcare Image
RestartResume

Expert insights for APPs from Dr Roy F. Chemaly on the latest clinically relevant data on the prevention and management of cytomegalovirus (CMV) infection in the setting of hematopoietic cell transplant.

Available credits: 1.00

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Dive in for expert insights for APPs from Dr Roy F. Chemaly, Professor of Medicine in the Department of Infectious Diseases, Infection Control, and Employee Health at The University of Texas MD Anderson Cancer Center in Houston. He’ll discuss the latest clinically relevant data on the prevention and management of cytomegalovirus (CMV) infection in the setting of hematopoietic cell transplant.

  • Disclosure of Conflicts of Interest

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Roy F. Chemaly, MD, MPH
    Professor of Medicine
    Department of Infectious Diseases, Infection Control, and Employee Health
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Roy F. Chemaly, MD, MPH:consultant/advisor/speaker: ADMA Biologics, AiCuris, Karius, Qiagen, Takeda; researcher: AiCuris, Ansun Pharmaceuticals, Karius, Merck, Takeda, Viracor; independent contractor: Merck.

    The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose. 

  • Target Audience

    This activity is intended for NPs and PAs who manage HSCT patients who are at risk for CMV infection.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Describe risk factors for CMV infection among HCT recipients
    • Apply guideline recommendations for use of prophylactic or preemptive strategies to prevent CMV
    • Evaluate evidence supporting use of therapies for CMV in HCT
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    ANCC Credit Designation
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacology credit.

    AAPA Credit Designation
    Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until July 20, 2024. PAs should only claim credit commensurate with the extent of their participation.
    IPCE Credit Designation 
    This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. 

  • Disclosure ogf Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

     
    Provided by Partners for Advancing Clinical Education (PACE) 

  • Commercial Support

    Supported by an educational grant from Merck Sharp & Dohme, LLC.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free